You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海凱寶(300039.SZ):痰熱清注射液列入第九版新冠病毒肺炎診療方案
格隆匯 03-16 11:45

格隆匯3月16日丨上海凱寶(300039.SZ)公佈,2022年3月15日,國家衞生健康委和國家中醫藥管理局聯合發佈《新型冠狀病毒肺炎診療方案(試行第九版)》。公司產品痰熱清注射液被該方案列為臨牀治療期(確診病例)重型和危重型推薦用藥。

公司主營產品痰熱清注射液是獨家專利、國家中藥保護和國家醫保目錄(乙類)品種,屬國家中藥二類新藥,主要用於細菌或病毒引起的急慢性支氣管炎、肺炎及上呼吸道感染疾病的治療。痰熱清注射液自2003年上市以來,先後多次被國家衞生健康委、國家中醫藥管理局列入重大疫情臨牀指南或診療方案;連續被列為《新型冠狀病毒肺炎診療方案(試行第六/七/八版)》臨牀治療期(確診病例)重型和危重型推薦用藥。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account